Stock Graphs and Charts
This is a complete list of financial data submitted by Antares Pharma, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. These terms are taken from the XBRL portion of the filings.
Click on a term to see historical data and generate a time series chart from the historical filings.
Peers - Surgical and Medical Instruments and Apparatus (3841)
AMDA / Amedica Corporation
CASM / CAS Medical Systems, Inc.
CYTX / Cytori Therapeutics, Inc.
DRIO / DarioHealth Corp
DSCI / Derma Sciences, Inc.
GID / GI DYNAMICS, INC.
HART / Harvard Apparatus Regenerative Technology, Inc.
ICAD / icad, inc.
MDXG / MiMedx Group, Inc.
Related News Stories
A study from 2009 by Alok Kumar found retail investors exhibit “a greater propensity to gamble” as compared to institutional investors. (62-1)
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested. (627-6)
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme. (666-4)
Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron (GERN), Antares Pharma (ATRS) and AcelRX (ACRX). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold or buy more. Thus far, all three well overperformed both the Nasdaq (QQQ) as well as their small biotech (SBIO) peer group. (75-1)
Company remains a viable acquisition candidate, especially in the likely aftermath of Xyosted being approved by the FDA. (68-0)